Close

Five Prime Therapeutics (FPRX) Announces Pact with Roche to Develop Companion Diagnostics for Targeted Immuno-Oncology Investigational Drug Candidates

May 30, 2018 4:09 PM EDT Send to a Friend
Five Prime Therapeutics, Inc. (Nasdaq: FPRX), a clinical-stage biotechnology company focused on discovering and developing innovative immuno-oncology protein therapeutics, today ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login